Pulmonary hypertension in patients with chronic myeloproliferative disorders

Eur Respir Rev. 2015 Sep;24(137):400-10. doi: 10.1183/16000617.0041-2015.

Abstract

Pulmonary hypertension (PH) is a major complication of several haematological disorders. Chronic myeloproliferative diseases (CMPDs) associated with pulmonary hypertension have been included in group five of the clinical classification for pulmonary hypertension, corresponding to pulmonary hypertension for which the aetiology is unclear and/or multifactorial. The aim of this review is to discuss the epidemiology, pathogenic mechanism and treatment approaches of the more common forms of pulmonary hypertension in the context of CMPD's: chronic thromboembolic pulmonary hypertension, precapillary pulmonary hypertension and drug-induced PH.

Publication types

  • Review

MeSH terms

  • Animals
  • Antihypertensive Agents / therapeutic use
  • Arterial Pressure* / drug effects
  • Chronic Disease
  • Endarterectomy
  • Humans
  • Hypertension, Pulmonary / diagnosis
  • Hypertension, Pulmonary / etiology*
  • Hypertension, Pulmonary / physiopathology
  • Hypertension, Pulmonary / therapy*
  • Myeloproliferative Disorders / complications*
  • Myeloproliferative Disorders / diagnosis
  • Myeloproliferative Disorders / drug therapy
  • Protein Kinase Inhibitors / adverse effects
  • Pulmonary Artery / drug effects
  • Pulmonary Artery / physiopathology*
  • Pulmonary Artery / surgery
  • Risk Assessment
  • Risk Factors
  • Thromboembolism / etiology
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Protein Kinase Inhibitors